Ítem
Acceso Abierto

Response to Letter to the Editor on “Rivaroxaban Use for Thromboprophylaxis Is Associated With Early Periprosthetic Joint Infection”

dc.creatorKlika, Alison Kspa
dc.creatorBrimmo, Olubusolaspa
dc.creatorMurray, Trevor Gspa
dc.creatorMolloy, Robertspa
dc.creatorHiguera, Carlos Aspa
dc.date.accessioned2020-07-30T21:01:52Z
dc.date.available2020-07-30T21:01:52Z
dc.date.created2016-09spa
dc.description.abstractTo the Editor: We would like to thank the authors for their input regarding our article entitled “Rivaroxaban Use for Thrombosis Prophylaxis Is Associated With Early Periprosthetic Joint Infection” [1]. As the authors noted, in the RECORD randomized controlled trials, no statistical differences in safety were reported [2, 3, 4, 5]. However, the adverse events that were well described in the methodology were primarily limited to bleeding events. There was no description of postoperative wound infection, how this was defined, or for what time point this was measured. In the absence of these details, we assumed that these data were reported for the treatment period, which was 14 days postoperative. This is a diversion from the methodology used in our study, in which patients were followed postoperatively for 30 days. In summary, although we agree with the authors that these trials did not show any statistical differences in terms of infection, we feel that this may have been a cursory look at the wrong time point for this outcome. In response to the comment regarding potential confounders contributing to our results (eg, steroid use, comorbidities, history of smoking, and so forth), we were not able to statistically adjust for these factors owing to the low incidence of early deep surgical site infections in our cohort as we noted in our limitations. However, we did perform univariate comparisons of the 2 treatment groups, and no statistically significant differences were observed between the 2 groups. We have discontinued the use of rivaroxaban at our institution, as it is our opinion that its benefits do not outweigh its risks.eng
dc.format.mimetypeapplication/pdf
dc.identifier.doihttps://doi.org/10.1016/j.arth.2016.05.017
dc.identifier.issnISSN: 0883-5403
dc.identifier.issnEISSN: 1532-8406
dc.identifier.urihttps://repository.urosario.edu.co/handle/10336/25671
dc.language.isoengspa
dc.publisherThe Journal of Arthroplastyspa
dc.relation.citationEndPage2080
dc.relation.citationIssueNo. 9
dc.relation.citationStartPage2079
dc.relation.citationTitleThe Journal of Arthroplasty
dc.relation.citationVolumeVol. 31
dc.relation.ispartofThe Journal of Arthroplasty, ISSN: 0883-5403 ; EISSN: 1532-8406, Vol.31, No.9 (2016); pp. 2079-2080spa
dc.relation.urihttps://www.arthroplastyjournal.org/action/showPdf?pii=S0883-5403%2816%2930155-3spa
dc.rights.accesRightsinfo:eu-repo/semantics/openAccess
dc.rights.accesoAbierto (Texto Completo)spa
dc.source.instnameinstname:Universidad del Rosariospa
dc.source.reponamereponame:Repositorio Institucional EdocURspa
dc.subjectArtritisspa
dc.subjectInfecciosaspa
dc.subjectArtroplastiaspa
dc.subjectReemplazospa
dc.subjectRodillaspa
dc.subjectHumanosspa
dc.subjectMorfolinasspa
dc.subjectRivaroxabánspa
dc.subject.keywordArthritisspa
dc.subject.keywordInfectiousspa
dc.subject.keywordArthroplastyspa
dc.subject.keywordReplacementspa
dc.subject.keywordKneespa
dc.subject.keywordHumansspa
dc.subject.keywordMorpholinesspa
dc.subject.keywordRivaroxabanspa
dc.titleResponse to Letter to the Editor on “Rivaroxaban Use for Thromboprophylaxis Is Associated With Early Periprosthetic Joint Infection”spa
dc.title.TranslatedTitleRespuesta a la carta al editor sobre 'El uso de rivaroxabán para la tromboprofilaxis está asociado con la infección temprana de la articulación periprotésica'spa
dc.typerevieweng
dc.type.hasVersioninfo:eu-repo/semantics/publishedVersion
dc.type.spaArtículospa
Archivos
Bloque original
Mostrando1 - 1 de 1
Cargando...
Miniatura
Nombre:
1-s2-0-S0883540316301565-main.pdf
Tamaño:
194.86 KB
Formato:
Adobe Portable Document Format
Descripción:
Colecciones